SAN DIEGO , Dec. 16, 2025 /PRNewswire/ --Â Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference:
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention.
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director
3 Reasons to Sell ILMN and 1 Stock to Buy Instead
3 Unpopular Stocks with Warning Signs
1 Momentum Stock with Promising Prospects and 2 We Avoid
Study shows that rare variants captured by Illumina WGS with DRAGENâ„¢ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood...
SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed